Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report published on Thursday,Benzinga reports. The firm currently has a $18.00 price target on the stock.

Other analysts have also recently issued reports about the company. Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, August 12th. BTIG Research reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Finally, Roth Capital reissued a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA traded down $0.14 during mid-day trading on Thursday, hitting $3.13. 189,167 shares of the stock traded hands, compared to its average volume of 174,773. Coya Therapeutics has a twelve month low of $2.72 and a twelve month high of $6.62. The company has a market cap of $73.43 million, a PE ratio of -2.25 and a beta of 0.70. The firm has a 50 day simple moving average of $4.29 and a two-hundred day simple moving average of $4.58.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.11). The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.11 million. Coya Therapeutics had a negative return on equity of 71.48% and a negative net margin of 643.44%. On average, equities research analysts anticipate that Coya Therapeutics will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers raised its holdings in shares of Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after purchasing an additional 8,000 shares during the last quarter. Allworth Financial LP boosted its holdings in Coya Therapeutics by 1,200.0% during the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock worth $76,000 after purchasing an additional 12,000 shares during the last quarter. AXQ Capital LP purchased a new position in Coya Therapeutics during the second quarter worth about $116,000. Renaissance Technologies LLC grew its position in Coya Therapeutics by 55.4% in the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after purchasing an additional 37,064 shares in the last quarter. Finally, Long Corridor Asset Management Ltd bought a new stake in Coya Therapeutics in the 2nd quarter worth about $227,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.